I’ve decided that I will focus on Alzheimer’s disease, specifically its link to type 2 diabetes, for my Capstone project. Alzheimer’s disease is a type of neurodegenerative dementia that has long been a mystery to solve for scientist. So far, two types of Alzheimer’s disease have been discovered: familial and sporadic. Sporadic Alzheimer’s disease is more common than the familial form, which is characterized by its unusually early onset (late 30’s to early 40’s). I will have three categories: Alzheimer’s Disease Types, Causes, and Diagnostic Tests, Mechanisms, and Proposed Treatments.
The first category will be used to give readers an introduction to the disease, some of it’s history, along with some statistical information. I will also differentiate between the two known types of Alzheimer’s disease as well as various diagnostic tests. The disease’s relationship with amyloid beta and APP will be defined and described to readers. Towards the end of this category, I will start to introduce the possibility of a third type and provide a brief summary of diabetes link to Alzheimer’s disease.
The second category will be discussing the multiple mechanisms associated with Alzheimer’s disease. A brief analysis of it’s relationship to mitochondrial function, the protein tau, and lysosomal disorders will be introduced so readers will know the different paths taken to understand Alzheimer’s disease. It will then transition to discussing the most recent papers published that show a link between the disease and diabetes. This will open with the background necessary to understand the insulin’s role in diabetes, and then take readers into the discovery of insulin receptors in the brain.
Since a cure has not been found for Alzheimer’s disease, the last category will go over various treatment options that were thought to have worked in humans, and treatment options that are currently in trial. Options like Solanezumab and Rivastigmine hold a lot of hope as a viable treatment. Solanezumab uses monoclonal antibodies to target amyloid beta, and Rivastigmine is used as a cholinesterase inhibitor to delay the breakdown of acetylcholine in synapses.
I think the literature that I have read and collected so far provides a great foundation for me to start building my project. However, I would like to spend more time researching different proposed treatment options over the years as well as any that target diabetes linked Alzheimer’s disease.